Amgen, Inc. (AMGN:NASD) – 企業レポート

Report Summary

Amgen, Inc. (AMGN:NASD) Strategic SWOT, PESTLE, Value Chain Analysis and Financial Insight – A 360° Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, Financial and Operational KPI’s, and Recent Trends Report is a comprehensive and easily accessible overview of Amgen, Inc.’s business operations. It provides a detailed analysis of the company’s financial and strategic standing, as well as its position in the industry compared to competitors. The report includes several key features to facilitate decision-making and provide insights into the company’s performance.

The report begins with in-depth information about Amgen, Inc. including key insights, business segments, key executives, locations, products and services, historical events, corporate strategy, and management discussions. This section provides a solid foundation for understanding the company’s key attributes.

Next, the report assesses Amgen, Inc.’s strategic standing through various analyses. The ESG spotlight evaluates the company’s environmental, social, and governance performance, providing insights into its sustainability efforts and ethical practices. The SWOT analysis examines the company’s internal strengths and weaknesses, as well as external opportunities and threats. The PESTLE analysis evaluates the external factors impacting the company’s operations and market environment. Additionally, the value chain analysis identifies value-adding activities and areas for operational optimization. By integrating these strategic analyses, the report offers a comprehensive understanding of Amgen, Inc.’s overall strategic standing and supports informed decision-making and strategic planning.

The report also covers Amgen, Inc.’s financial analysis basis of latest income statement, balance sheet, and cash flow statement. Key financial ratios related to profitability, asset turnover, credit, market, and long-term solvency are outlined, providing guidance for investment decisions. Furthermore, the report compares Amgen, Inc.’s financial parameters with those of its competitors, offering a unique analysis of the competitive landscape. This information helps manage the business environment and improve sales activities by gaining insight into competitors’ operations.

Finally, the report includes recent news and deal activities undertaken by Amgen, Inc. enhancing awareness of the company’s business trends, growth perspectives, and more.

Key Highlights

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on areas such as inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience. Amgen Inc. operates in two main business segments: human therapeutics and biosimilars. The human therapeutics segment focuses on treating conditions such as cancer, inflammation, bone health, cardiovascular disease, and nephrology. The biosimilars segment develops and commercializes biosimilar versions of innovator biologics. Amgen Inc. offers a range of therapeutics to treat conditions such as plaque psoriasis, rheumatoid arthritis, anemia, multiple myeloma, osteoporosis, and more. Some of its key products include Enbrel, Neulasta, Prolia, Xgeva, Otezla, Aranesp, and Kyprolis. It also markets drugs like Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, and Sensipar. Founded in 1980, the company is headquartered in Thousand Oaks, California, United States.

Amgen, Inc. in the News:-

 - 03-Aug-2023  - Amgen reports second quarter financial results  - 19-Apr-2023  - Amgen wins patent appeal on otezla® (apremilast)  - 31-Jan-2023  - Amjevita™ (adalimumab-atto), first biosimilar to humira®, now available in the united states  - 06-Jan-2023  - Amgen presents new scientific and clinical research across its diverse oncology portfolio and pipeline at asco 2023  - 04-Jan-2023  - Amgen to present at the 41st annual j.P. Morgan healthcare conference

Scope

• Tactical Analysis:- Various strategic frameworks to gain insights into a company’s competitive position and operational environment. These analytical tools assist in identifying competitive advantages, potential risks, and areas for improvement and efficiency, enabling companies to make informed tactical decisions.
• Business Strategy:- Contributes to shaping the company’s overall direction, goals, and decision-making processes, ensuring long-term success and alignment with stakeholder expectations.
• Financial Position:- Provide valuable information on the financial performance and investor sentiment surrounding the company. Indicating the level of confidence and expectations in the company’s future prospects. These components collectively contribute to understanding the financial health and market perception of the company.
• Company Fundamentals:- These fundamentals offer valuable insights into the company’s history, operations, leadership, and geographical presence, aiding in a comprehensive understanding of the organization.
• Competitive Landscape:- An identification of the company’s main competitors, providing insights into the competitive landscape it operates in.

Reasons to Buy

• Comprehensive Understanding of the Amgen, Inc.’s internal and external factors through SWOT analysis, PESTLE analysis, Value Chain analysis, Financial Analysis, and Competitors Benchmarking.
• Strive Strategic Decision Making with various analyses and identifying potential customers and suppliers.
• Mitigate Risk with help of thorough analysis of internal and external factors. Furthermore, develop strategies and contingency plans to address these challenges and minimize their impact on business operations.
• Competitive Benchmarking will help to gain a competitive advantage by understanding industry trends, customer preferences, and best practices.
• Financial Performance Evaluation provides crucial insights into key financial ratios and trends, supporting better financial decision-making and resource allocation.
• Valuable insights from the report enable investors and partners to make informed decisions regarding potential Collaborations, Investments, or Partnerships with the company.

Additionally, available deep-dive analysis on the company Amgen, Inc.:

• Amgen, Inc. Porter’s Five Forces Analysis
• Amgen, Inc. VRIO Analysis
• Amgen, Inc. BCG Analysis
• Amgen, Inc. Segmentation, Targeting and Positioning (STP) Analysis
• Amgen, Inc. Ansoff Matrix Analysis

COMPANY EXECUTIVE SUMMARY

Table of Contents
Tables
Charts
Amgen, Inc. – Key Company Facts
Amgen, Inc. – Company Description
Amgen, Inc. – Top Executives
Amgen, Inc. – Top Executives Biographies
Amgen, Inc. – Head Office & Locations
Head Office – Country
Key Subsidiaries
Key Joint Ventures
Amgen, Inc. – Products and Services
Products
Amgen, Inc. – Historic Events
Amgen, Inc. – Company’s Management Discussion
Amgen, Inc. – Company’s Mission and Vision
Mission
Amgen, Inc. – Corporate Strategy
Amgen, Inc. – Business Description
Therapeutic Focus Areas
Product Portfolio
Global Distribution Network
Collaborative Ventures
Research and Development (R&D)
Amgen, Inc. – ESG Spotlight
Environment
Social
Corporate Governance
Amgen, Inc. – SWOT Analysis
Overview
Strengths
Weaknesses
Opportunities
Threats
Amgen, Inc. – PESTLE Analysis
Overview
Political Factors
Economic Factors
Social Factors
Technological Factors
Legal Factors
Environmental Factors
Amgen, Inc. – Value Chain Analysis
Overview
Primary Activities
Inbound Logistics
Operations
Outbound Logistics
Marketing and Sales
Service
Support Activities
Procurement
Technology
Human Resource
Firm Infrastructure
Amgen, Inc. – Financial Deep Dive
Share Price Trend – Jan-2023 to Jan-2024 (Average Share Closing Price)
Profit and Loss Statement
Summary of Profit and Loss Statement
Balance Sheet
Summary of Balance Sheet
Cash Flow Statement
Summary of Cash Flow Statement
Key Financial Ratio Analysis
Amgen, Inc. – Ratio Charts
Activity Ratio Charts
Growth Ratios Charts
Leverage Ratio Charts
Liquidity Ratio Charts
Profitability Ratio Charts
Competing Players
Snapshot of Competing Players
Bristol-Myers Squibb Co
Key Company Facts
Company Description
Gilead Sciences Inc.
Key Company Facts
Company Description
Regeneron Pharmaceuticals Inc
Key Company Facts
Company Description
Vertex Pharmaceuticals Incorporated
Key Company Facts
Company Description
Zoetis Inc
Key Company Facts
Company Description
Amgen, Inc. – Key Deals
06-Oct-2023 – Amgen completes acquisition of horizon therapeutics plc
09-May-2023 – Amgen and TScan Therapeutics announce collaboration to identify novel targets in crohn’s disease
12-Dec-2022 – Amgen agrees to acquire horizon therapeutics for $27.8 billion
20-Oct-2022 – Amgen successfully completes acquisition of chemocentryx
27-Jul-2021 – Amgen to acquire privately held teneobio for $900 million in cash with future contingent milestone payments
16-Apr-2021 – Amgen successfully completes acquisition of five prime therapeutics
Amgen, Inc. – In the News
14-Dec-2023 – Amgen announces executive appointments to accelerate innovation
07-Nov-2023 – Amgen presents new research in early psoriatic arthritis at acr 2023
20-Oct-2023 – Amgen presents new tarlatamab data in small cell lung cancer
20-Sep-2023 – Amgen launches partners of choice network of eight leading oncology academic centers
03-Aug-2023 – Amgen reports second quarter financial results
19-Apr-2023 – Amgen wins patent appeal on otezla® (apremilast)
31-Jan-2023 – Amjevita™ (adalimumab-atto), first biosimilar to humira®, now available in the united states
06-Jan-2023 – Amgen presents new scientific and clinical research across its diverse oncology portfolio and pipeline at asco 2023
04-Jan-2023 – Amgen to present at the 41st annual j.P. Morgan healthcare conference
03-Aug-2022 – Amgen appoints michael v. Drake to board of directors
26-May-2022 – New data showcases how amgen is advancing all angles of cancer care through innovative oncology portfolio and pipeline at asco 2022
07-Mar-2022 – Global biotechnology leader amgen breaks ground on new manufacturing facility in north carolina
22-Feb-2022 – Amgen issues inaugural green bond to advance esg goals
Appendix
Definitions
SWOT Analysis
PESTLE Analysis
Value Chain Analysis
ESG Spotlight
Financial Deep Dive
Financial Ratios –
Activity Ratios
Growth Ratios
Leverage Ratios
Liquidity Ratios
Market Ratios
Profitability Ratios
Research Methodology
Disclaimer
Contact Us

Tables

Table 1: Amgen, Inc. – Company Facts
Table 2: Amgen, Inc. – Top Executives
Table 3: Amgen, Inc. – Top Executives Biographies
Table 4: Amgen, Inc. – Subsidiaries
Table 5: Amgen, Inc. – Key Joint Ventures
Table 6: Amgen, Inc. – Products
Table 7: Amgen, Inc. – Historic Events
Table 8: Amgen, Inc. – Share Price Trend – Jan-2023 to Jan-2024
Table 9: Amgen, Inc. – Ratio Analysis – 2019-2022
Table 10: Amgen, Inc. – Competing Players
Table 11: Competing Players – Bristol-Myers Squibb Co – Key Company Facts
Table 12: Competing Players – Bristol-Myers Squibb Co – Key Financials
Table 13: Competing Players – Gilead Sciences Inc. – Key Company Facts
Table 14: Competing Players – Gilead Sciences Inc. – Key Financials
Table 15: Competing Players – Regeneron Pharmaceuticals Inc – Key Company Facts
Table 16: Competing Players – Regeneron Pharmaceuticals Inc – Key Financials
Table 17: Competing Players – Vertex Pharmaceuticals Incorporated – Key Company Facts
Table 18: Competing Players – Vertex Pharmaceuticals Incorporated – Key Financials
Table 19: Competing Players – Zoetis Inc – Key Company Facts
Table 20: Competing Players – Zoetis Inc – Key Financials

Charts

Figure 1: Amgen, Inc. – SWOT Analysis
Figure 2: Amgen, Inc. – PESTLE Analysis
Figure 3: Amgen, Inc. – Value Chain Analysis
Figure 4: Amgen, Inc. – Average Share Price Trend – Jan-2023  to Jan-2024
Figure 5: Amgen, Inc. – Profit and Loss Statement – 2019-2022
Figure 6: Amgen, Inc. – Balance Sheet – 2019-2022
Figure 7: Amgen, Inc. – Cash Flow Statement 2019-2022
Figure 8: Amgen, Inc. – Activity Ratio Charts
Figure 9: Amgen, Inc. – Growth Ratio Charts (Value %)
Figure 10: Amgen, Inc. – Leverage Ratio Charts
Figure 11: Amgen, Inc. – Liquidity Ratio Charts
Figure 12: Amgen, Inc. – Profitability Ratio Charts (Value %)
Figure 13: Competing Players – Bristol-Myers Squibb Co – Key Financials
Figure 14: Competing Players – Gilead Sciences Inc. – Key Financials
Figure 15: Competing Players – Regeneron Pharmaceuticals Inc – Key Financials
Figure 16: Competing Players – Vertex Pharmaceuticals Incorporated – Key Financials
Figure 17: Competing Players – Zoetis Inc – Key Financials